Elevated level of serum human epididymis protein 4 (HE4) predicts disease severity and mortality in COVID-19 pneumonia

被引:0
|
作者
Suto, Renata [1 ,2 ,3 ]
Pocsi, Marianna [1 ]
Szabo, Zsolt [3 ]
Fejes, Zsolt [1 ]
Ivady, Gergely [1 ]
Kerekes, Gyoergy [4 ]
Fagyas, Miklos [5 ]
Nagy, Attila [6 ]
Szentkereszty, Zoltan [3 ]
Kappelmayer, Janos [1 ]
Nagy Jr, Bela [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Lab Med, Debrecen, Hungary
[2] Univ Debrecen, Fac Med, Doctoral Sch Kalman Laki, Debrecen, Hungary
[3] Univ Debrecen, Fac Med, Intens Care Unit, Gyula Kenezy Campus, Debrecen, Hungary
[4] Univ Debrecen, Fac Med, Dept Internal Med, Intens Care Unit, Debrecen, Hungary
[5] Univ Debrecen, Fac Med, Dept Cardiol, Div Clin Physiol, Debrecen, Hungary
[6] Univ Debrecen, Fac Publ Hlth, Dept Prevent Med, Debrecen, Hungary
关键词
SARS-CoV-2; Inflammation; COVID-19; Disease; Pneumonia; Biomarker; HE4; Outcome; RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL; TUMOR-MARKER; HOMOLOGY; SEPSIS;
D O I
10.1186/s12890-023-02811-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background We retrospectively analyzed serum level of human epididymis protein 4 (HE4) as a pulmonary inflammatory biomarker in patients with COVID-19 pneumonia in association with disease severity and outcome.Methods Ninety-nine (40 critically ill, 40 severe and 19 mild) COVID-19 patients and as controls 25 age- and sex-matched non-COVID-19 bacterial sepsis subjects were included. Serum HE4 was measured by an immunoassay (Architect (R) i1000SR, Abbott) in the baseline samples of all study participants obtained at intensive care unit (ICU) admission or during outpatient clinic visit and follow-up sera were available in case of 30 COVID-19 subjects with life-threating conditions. Associations were studied between serum HE4, routinely available laboratory parameters, clinical characteristics, and disease progression.Results Baseline HE4 level was significantly higher (P < 0.0001) in critically ill (524.7 [300.1-1153.0] pmol/L) than severe COVID-19 subjects (157.4 [85.2-336.9] pmol/L) and in mild SARS-CoV-2 infection (46.7 [39.1-57.2] pmol/L). Similarly increased HE4 concentrations were found in bacterial sepsis (1118.0 [418.3-1953.0] pmol/L, P = 0.056) compared to critically ill COVID-19 individuals. Serum HE4 levels significantly correlated with age, SOFA-score, inflammation-dependent biomarkers, and the degree of lung manifestation evaluated by chest CT examination in ICU COVID-19 individuals. Based on ROC-AUC curve analysis, baseline HE4 independently indicated the severity of COVID-19 with an AUC value of 0.816 (95% CI [0.723-0.908]; P < 0.0001), while binary logistic regression test found HE4 as an independent prognostic parameter for death (OR: 10.618 [2.331-48.354]; P = 0.002). Furthermore, COVID-19 non-survivors showed much higher baseline HE4 levels without a substantial change under treatment vs. survivors (P < 0.0001). Finally, pre-treatment HE4 level of >= 331.7 pmol/L effectively predicted a larger risk for mortality (Log-Rank P < 0.0001) due to severe COVID-19 pneumonia.Conclusion Elevated serum HE4 level at ICU admission highly correlates with COVID-19 severity and predicts disease outcome.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Serum Human Epididymis Protein 4 (HE4) in the Differential Diagnosis of Peritoneal Tuberculosis: A Report of Two Cases
    Kabaca, Canan
    Dolgun, Zehra Nihal
    Telci, Aysegul
    Karateke, Ates
    BALKAN MEDICAL JOURNAL, 2014, 31 (03) : 270 - 271
  • [22] Comparison of Serum Human Epididymis Protein 4 (HE4) Levels in Breast Cancer Patients and Healthy Individuals
    Zahra Honarvar
    Behjat Kalantari Khandani
    Mohaddeseh Nazari
    Fatemeh Karami Robati
    Indian Journal of Gynecologic Oncology, 2021, 19
  • [23] Comparison of Serum Human Epididymis Protein 4 (HE4) Levels in Breast Cancer Patients and Healthy Individuals
    Honarvar, Zahra
    Khandani, Behjat Kalantari
    Nazari, Mohaddeseh
    Robati, Fatemeh Karami
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 19 (04)
  • [24] Human Epididymis Protein 4 (HE4). A tumor marker in the diagnosis of ovarian cancer
    Zulauf, N.
    Bendels, M. H.
    Bauer, J.
    Braun, M.
    Volante, G.
    Oremek, G. M.
    Groneberg, D. A.
    Brueggmann, D.
    ZENTRALBLATT FUR ARBEITSMEDIZIN ARBEITSSCHUTZ UND ERGONOMIE, 2019, 69 (01): : 30 - 32
  • [25] Diagnostic efficiency of human epididymis protein 4 (HE4) in differentiating pelvic cancers
    Montagnana, M.
    Lippi, G.
    Ruzzenente, O.
    Bresciani, V.
    Scevarolli, S.
    Danese, E.
    Salvagno, G. L.
    Minicozzi, A. M.
    Cordiano, C.
    Franchi, M.
    Guidi, G. C.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A117 - A117
  • [26] Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders
    Kappelmayer, Janos
    Antal-Szalmas, Peter
    Nagy, Bela, Jr.
    CLINICA CHIMICA ACTA, 2015, 438 : 35 - 42
  • [27] Clinical role of human epididymis protein 4 (HE4) in epithelial ovarian cancer
    Bandiera, E.
    Ragnoli, M.
    Zanotti, L.
    Bignotti, E.
    Romani, C.
    Tassi, R.
    Todeschini, P.
    Odicino, F.
    Ravaggi, A.
    Pecorelli, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 143 - 143
  • [28] Human epididymis protein 4 (HE4) is a novel immunohistochemical marker of neuroendocrine differentiation
    Su, Wenjing
    Yang, Kun
    Jiang, Huifeng
    Song, Haiyun
    Feng, Kun
    Li, Qiuyao
    VIRCHOWS ARCHIV, 2022, 481 (03) : 433 - 441
  • [29] Human epididymis protein 4 (HE4) is a novel immunohistochemical marker of neuroendocrine differentiation
    Wenjing Su
    Kun Yang
    Huifeng Jiang
    Haiyun Song
    Kun Feng
    Qiuyao Li
    Virchows Archiv, 2022, 481 : 433 - 441
  • [30] Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease
    Wan, Jianxin
    Wang, Yanhong
    Cai, Gaorong
    Liang, Jianbo
    Yue, Caifeng
    Wang, Fen
    Song, Junli
    Wang, Jianfeng
    Liu, Min
    Luo, Jinmei
    Li, Laisheng
    ONCOTARGET, 2016, 7 (42) : 67748 - 67759